A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Status:
Active, not recruiting
Trial end date:
2024-01-23
Target enrollment:
Participant gender:
Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel
oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung
Cancer (NSCLC)